Abstract Number: 2390 • 2019 ACR/ARP Annual Meeting
Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission
Background/Purpose: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying…Abstract Number: 2772 • 2019 ACR/ARP Annual Meeting
Clinical and Biological Changes in Rheumatoid Arthritis Patients Exposed to an Anti-inflammatory Diet
Background/Purpose: RA patients often inquire about dietary interventions to improve disease control, as they perceive quick changes in pain and/or swelling after consumption of certain…Abstract Number: 2872 • 2019 ACR/ARP Annual Meeting
Risk of 30-day Readmission and Adverse Events After Primary Hip or Knee Arthroplasty: A Comparison of Patients with Rheumatoid Arthritis versus Osteoarthritis Using the Nationwide Readmission Database
Background/Purpose: To assess the risk of 30-day readmission, mortality, and adverse events among adults with Rheumatoid Arthritis as compared to Osteoarthritis after primary hip or…Abstract Number: 36 • 2019 ACR/ARP Annual Meeting
Discovery, Verification and Validation of Rheumatoid Arthritis Activity Monitoring Biomarkers
Background/Purpose: Rheumatoid arthritis (RA) is a long-lasting inflammatory autoimmune disorder that ultimately leads to the destruction of joint architecture. The activity of this disease is…Abstract Number: 117 • 2019 ACR/ARP Annual Meeting
The Indole Derivative NecroX Blocks Th17 Cell Differentiation and Fibroblast-like Synoviocytes-mediated Th1/Th17 Responses in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of synovium, which causes progressive joint destruction and reduction in quality of life.…Abstract Number: 196 • 2019 ACR/ARP Annual Meeting
Risk of Subsequent Atherosclerotic Cardiovascular Disease After the First Unprovoked Venous Thromboembolism in Patients with Rheumatoid Arthritis
Background/Purpose: With the advent of JAK inhibitors has come increased concerns for the risk of venous thromboembolism (VTE), which was already known to be increased…Abstract Number: 315 • 2019 ACR/ARP Annual Meeting
Improving the Rate of Tuberculosis Screening Among High Risk Rheumatoid Arthritis Patients on Biologic Agents Using a Proposed Questionnaire
Background/Purpose: The use of biologics has transformed the treatment paradigm for RA; however, reactivation of Mycobacterium Tuberculosis is still a concern. Frequent TB screenings without…Abstract Number: 454 • 2019 ACR/ARP Annual Meeting
Principal Component Analysis Identifies Unique Sub-Populations in Rheumatoid Arthritis Using a Combination of Serological Biomarkers: A Cross Sectional Study
Background/Purpose: Determining the prognosis of rheumatoid arthritis (RA) could guide more precise treatment selection, optimizing outcomes while minimizing unnecessary therapeutic exposures. It is important that…Abstract Number: 488 • 2019 ACR/ARP Annual Meeting
Citrullinated Antigens with Multiple Citruline Similar Motif Could Be Used for RA Diagnosis
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic joint inflammation that ultimately leads to joint destruction. Diagnosis of RA is important…Abstract Number: 535 • 2019 ACR/ARP Annual Meeting
Exploratory Analysis of a Phase 2b Study Confirms Substantial Pain Improvement with Anti-GM-CSF Monoclonal Antibody Otilimab (GSK3196165) in Patients (Pts) with Active RA
Background/Purpose: Treatment of pain remains a priority for patients (pts) with RA. Otilimab (GSK3196165) is a human mAb that inhibits GM-CSF, a key driver in…Abstract Number: 840 • 2019 ACR/ARP Annual Meeting
Trajectory of Multimorbidity in Rheumatoid Arthritis in a U.S. Commercial Insurance Claims Database from 2006-2015
Background/Purpose: Multimorbidity, the presence of multiple chronic conditions, predisposes individuals to disability and premature mortality. RA is well known to be associated with select chronic…Abstract Number: 956 • 2019 ACR/ARP Annual Meeting
The Impact of Psychiatric Comorbidity on Health Care Utilization and Preventive Health Care in Rheumatoid Arthritis: A Population Based Study
Background/Purpose: Psychiatric comorbidity is increased in rheumatoid arthritis (RA) and may complicate medical care, increasing the risk of adverse health outcomes and health care utilization…Abstract Number: 1170 • 2019 ACR/ARP Annual Meeting
Cortical Bone Erosion in the 2nd Metacarpal Bone Head: Association with Its Bone Mineral Density by HR-pQCT in Rheumatoid Arthritis Patients
Background/Purpose: Periarticular trabecular bone loss and local cortical bone erosions are typical features of bone disease in rheumatoid arthritis (RA) 1 . Little, however, is…Abstract Number: 1343 • 2019 ACR/ARP Annual Meeting
Pop a Pill or Give Myself a Shot? Patient Perspectives of Disease-modifying Anti-rheumatic Drug (DMARD) Choice for Rheumatoid Arthritis (RA)
Background/Purpose: Little is known about the patient perspective related to DMARD choice in RA. Our objective was to assess how patients decide whether to add…Abstract Number: 1370 • 2019 ACR/ARP Annual Meeting
Not All Joints Are Equal: Challenge DAS28 System and Identify Factors Leading to a Mismatch Between T2T and HAQ Among RA Patients Through Data Mining from Smart System of Disease Management (SSDM)
Background/Purpose: Treat to target (T2T), achieving a DAS28 score lower than 3.2, is the strategy recommended by ACR and EULAR. Health assessment questionnaire (HAQ) is…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 56
- Next Page »